4.6 Article

Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis

期刊

PLOS ONE
卷 8, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0063864

关键词

-

向作者/读者索取更多资源

Background: To report the feasibility, efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for the treatment of portal vein tumor thrombosis (PVTT) and/or inferior vena cava tumor thrombosis (IVCTT) in patients with advanced hepatocellular carcinoma (HCC). Materials and methods: Forty-one patients treated with SBRT using volumetric modulated arc therapy (VMAT) for HCC with PVTT/IVCTT between July 2010 and May 2012 were analyzed. Of these, 33 had PVTT and 8 had IVCTT. SBRT was designed to target the tumor thrombosis and deliver a median total dose of 36 Gy (range, 30-48 Gy) in six fractions during two weeks. Results: The median follow-up was 10.0 months. At the time of analysis, 15 (36.6%) achieved complete response, 16 (39.0%) achieved partial response, 7 (17.1%) patients were stable, and three (7.3%) patients showed progressive disease. No treatment-related Grade 4/5 toxicity was seen within three months after SBRT. One patient had Grade 3 elevation of bilirubin. The one-year overall survival rate was 50.3%, with a median survival of 13.0 months. The only independent predictive factor associated with better survival was response to radiotherapy. Conclusions: VMAT-based SBRT is a safe and effective treatment option for PVTT/IVCTT in HCC. Prospective randomized controlled trials are warranted to validate the role of SBRT in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radia-tion Therapy: A Retrospective Study with 15-Year Follow-up

Lin Wang, Jingjing Miao, Huageng Huang, Boyu Chen, Xiao Xiao, Manyi Zhu, Yingshan Liang, Weiwei Xiao, Shaomin Huang, Yinglin Peng, Xiaowu Deng, Xing Lv, Weixiong Xia, Yanqun Xiang, Xiang Guo, Fei Han, Chong Zhao

Summary: This study investigated the long-term survival rates and toxicities of early-stage nasopharyngeal carcinoma (NPC) in an endemic area. The results showed that intensity-modulated radiotherapy (IMRT) can achieve superior tumor control and satisfactory long-term outcomes with mild late toxicities in early-stage NPC patients. Chemotherapy should be carefully performed in stage II patients due to increased toxicities.

CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

Comparison of Absolute Dose Achievable Between Helical Tomotherapy and RapidArc in Total Dura Mater Irradiation for Child Cancer

Wenzhao Sun, Jun Zhang, Yixuan Wang, Meining Chen, Jianli Wang, Li Chen, Lixia Lu, Xiaowu Deng

Summary: This study compared the effects of helical tomotherapy (HT) and RapidArc (RA) in total dura mater irradiation (TDMI) and found that HT provided a more homogenous dose distribution and lower dose to the central region of the brain. This may contribute to reducing long-term cognitive decline in young patients.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Radioprotective effect of X-ray abdominal FLASH irradiation: Adaptation to oxidative damage and inflammatory response may be benefiting factors

Hongyu Zhu, Dehuan Xie, Yiwei Yang, Shaomin Huang, Xingwang Gao, Yinglin Peng, Bin Wang, Jianxin Wang, Dexin Xiao, Dai Wu, Changzhi Li, Chenghua Li, Chao-Nan Qian, Xiaowu Deng

Summary: This study investigated the radiobiological response of ultrahigh dose-rate irradiation (FLASH-IR) using 6 MV X-ray and compared it with conventional dose-rate irradiation (CONV-IR). The results showed that FLASH-IR had a radioprotective effect, causing less acute intestinal damage compared to CONV-IR. Inflammatory responses and redox status also differed between the two groups.

MEDICAL PHYSICS (2022)

Article Oncology

Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma

Yu-Xian Yang, Yu-Zhen Zheng, Tian-Tian Gao, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Jun-Ye Wang, Shu-Nan Qi, Yong Yang, Lei Zhao

Summary: This study systematically evaluated 3-year progression-free survival and overall survival in patients with esophageal squamous cell cancer (ESCC). The results showed that patients who experienced progression within 3 years had poor survival outcomes, while those who achieved 3-year progression-free survival had excellent outcomes. 3-year progression-free survival can be used as a reliable primary endpoint for study design and risk stratification in locally advanced ESCC.

CANCER MEDICINE (2022)

Article Biochemistry & Molecular Biology

Trafficking protein TMED3 promotes esophageal squamous cell carcinoma

Yuxian Yang, Shiliang Liu, Chunxia Xie, Qiaoqiao Li, Tiantian Gao, Mengzhong Liu, Mian Xi, Lei Zhao

Summary: This study revealed the oncogenic role of TMED3 in esophageal squamous cell carcinoma (ESCC) and identified the overexpression of a TMED3-related protein FAM60A in ESCC tissues. Functional verification experiments demonstrated the important roles of TMED3 and FAM60A in ESCC cell proliferation and tumorigenicity.

BIOMEDICAL JOURNAL (2023)

Article Oncology

MR-based synthetic CT image for intensity-modulated proton treatment planning of nasopharyngeal carcinoma patients

Shupeng Chen, Yinglin Peng, An Qin, Yimei Liu, Chong Zhao, Xiaowu Deng, Rohan Deraniyagala, Craig Stevens, Xuanfeng Ding

Summary: This study developed an advanced deep convolutional neural network (DCNN) architecture to generate synthetic CT (SCT) images from MR images for intensity-modulated proton therapy (IMPT) treatment planning of nasopharyngeal cancer (NPC) patients. The SCT images generated using GANs achieved clinical acceptable dosimetric accuracy for IMPT of NPC patients. The use of advanced DCNN architecture design further improved SCT image quality and resulted in a small dosimetric improvement.

ACTA ONCOLOGICA (2022)

Review Oncology

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

Tian-Tian Gao, Jia-Hui Shan, Yu-Xian Yang, Ze-Wei Zhang, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Lei Zhao

Summary: This study compared the efficacy and safety of different immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). The results showed that Toripalimab and Camrelizumab plus chemotherapy were likely to be the best options in the first-line setting, while Sintilimab and Camrelizumab were preferred options for refractory patients. The toxicity related to immunotherapy was manageable.

BMC CANCER (2022)

Article Oncology

Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study

Huageng Huang, Jingjing Miao, Xiao Xiao, Jiang Hu, Guangshun Zhang, Yinglin Peng, Shunzhen Lu, Yingshan Liang, Shaomin Huang, Fei Han, Xiaowu Deng, Chong Zhao, Lin Wang

Summary: This study compares the incidence of xerostomia in nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT) and conventional IMRT (C-IMRT). The results show that SPLS-IMRT significantly reduces the incidence of xerostomia compared to C-IMRT, while also promoting earlier recovery of parotid gland function without compromising survival outcomes.

RADIOTHERAPY AND ONCOLOGY (2022)

Article Oncology

Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma A Randomized Clinical Trial

Jingjing Miao, Lin Wang, Sze Huey Tan, Jin-Gao Li, Junlin Yi, Enya H. W. Ong, Laura L. Y. Tan, Ye Zhang, Xiaochang Gong, Qiuyan Chen, Yan-Qun Xiang, Ming-Yuan Chen, Ying Guo, Xing Lv, Wei-Xiong Xia, Linquan Tang, Xiaowu Deng, Xiang Guo, Fei Han, Hai-Qiang Mai, Melvin L. K. Chua, Chong Zhao

Summary: In this randomized clinical trial, adjuvant capecitabine at the full dose following CCRT was well tolerated and improved failure-free survival among patients with LA-NPC and high-risk factors. Further investigations assessing optimal dose and duration are warranted.

JAMA ONCOLOGY (2022)

Article Oncology

Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning

Yinglin Peng, Yimei Liu, Guanzhu Shen, Zijie Chen, Meining Chen, Jingjing Miao, Chong Zhao, Jincheng Deng, Zhenyu Qi, Xiaowu Deng

Summary: In this study, a modified fully convolutional neural network called OrganNet was used for auto-segmentation of 24 organs at risk (OARs) in the head and neck. The model achieved good segmentation results, with an average Dice similarity coefficient of 83.75%. Specifically, it performed well in both large-volume organs and small-volume organs. Compared to manual-delineation, OrganNet showed comparable or better performance in organ segmentation based on the STAPLE contours.

ORAL ONCOLOGY (2023)

Article Oncology

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint

Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao

Summary: This study examines whether progression-free survival (PFS) can serve as a surrogate endpoint for overall survival (OS) in advanced Esophageal Squamous Cell Carcinoma (ESCC) treated with immunochemotherapy. The results show weak support for PFS as an OS surrogate in these cases. Additionally, continuous immunotherapy beyond progression may decrease the risk of death in qualified patients with advanced ESCC.

BMC CANCER (2023)

Article Oncology

A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial

Tiantian Gao, Yong Yang, Zewei Zhang, Yuxian Yang, Shiliang Liu, Yonghong Hu, Yujia Zhu, Hong Yang, Jianhua Fu, Junye Wang, Ting Lin, Mian Xi, Qiaoqiao Li, Mengzhong Liu, Lei Zhao

Summary: This study found that disease-free status at 36 months can serve as a valid surrogate endpoint for 5-year overall survival in patients with locally advanced and resectable esophageal squamous cell carcinoma. Patients who maintained disease-free status at 36 months had a favorable overall survival, while those who experienced disease progression within 36 months had a significantly poorer overall survival.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Oncology

Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059)

XinLei Ai, PengXin Zhang, XinMin Xie, Bo Qiu, YuJia Zhu, Lei Zhao, Mian Xi, YingJia Wu, SuPing Guo, JinYu Guo, FangJie Liu, DaQuan Wang, NaiBin Chen, QianWen He, YongHong Hu, MengZhong Liu, ZhaoXia Ding, Hui Liu

Summary: This study aimed to evaluate the efficacy and cost-effectiveness of pre-treatment percutaneous endoscopic gastrostomy (PEG) in patients with esophageal squamous cell carcinoma (ESCC) undergoing concurrent chemoradiotherapy (CCRT). The results showed that pre-treatment PEG improved the nutritional status and treatment outcomes, and it was cost-effective compared with oral nutritional supplements (ONS) and nasogastric tube feeding (NTF).

CANCER MEDICINE (2023)

Article Biochemistry & Molecular Biology

The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma

Boyu Chen, Runda Huang, Tianliang Xia, Chunyang Wang, Xiao Xiao, Shunzhen Lu, Xiangfu Chen, Ying Ouyang, Xiaowu Deng, Jingjing Miao, Chong Zhao, Lin Wang

Summary: In this study, the researchers found that IGF2BP3 acts as a key m6A reader in nasopharyngeal carcinoma (NPC) and maintains the stability of NOTCH3 mRNA through an m6A-dependent mechanism, thereby promoting tumor metastasis and enhancing the stemness phenotype. IGF2BP3 is associated with poor prognosis and may serve as a novel prognostic biomarker and therapeutic target in NPC metastasis.

ONCOGENE (2023)

Article Biochemistry & Molecular Biology

Mitochondrial energy metabolism correlates with an immunosuppressive tumor microenvironment and poor prognosis in esophageal squamous cell carcinoma

Zewei Zhang, Gaowa Jin, Juan Zhao, Shuqin Deng, Feng Chen, Gaowa Wuyun, Lei Zhao, Quanfu Li

Summary: This study analyzed mitochondrial energy metabolism (MEM) in the tumor micro-environment (TME) of esophageal squamous cell carcinoma (ESCC), identified relevant genes and cell populations, and found a relationship between immunosuppression and metabolic reprogramming. Prognostic models and potential immunotherapeutic targets contribute to personalized treatment.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

暂无数据